McEwen (MUX) Is Up 7.6% After Earnings Swing And New Lab MOU Is The Thesis Shifting?

• McEwen Inc. recently reported second-quarter 2026 results showing net income of US$9.61 million and a swing to profitability for the first half, and later revised its full-year 2026 production guidance to 109,000–120,000 gold equivalent ounces.
• Alongside this improved earnings profile, McEwen’s new memorandum of understanding with Paragon Advanced Labs Inc. points to a potential long-term enhancement in assay capabilities and revenue-sharing from third-party lab clients.
• We’ll now examine how McEwen’s strong earnings turnaround and updated 2026 production guidance may influence the company’s existing investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

McEwen Investment Narrative Recap

To own McEwen today, you have to believe it can translate its multi-asset gold and copper portfolio into consistent production and disciplined project execution. The latest swing to first-half profitability and reaffirmed 2026 output range support that view, but they also sharpen the focus on whether management can deliver near term production without repeating past shortfalls. The key risk remains operational underperformance or delays at assets like Tartan and Nevada, which could strain cash flow if capital needs rise.

The new memorandum of understanding with Paragon Advanced Labs is particularly relevant here, because it directly targets assay capacity and turnaround at Gold Bar, with potential extensions to Fox and El Gallo. Faster, more accurate assay results can support grade control, exploration decisions and, ultimately, the reliability of that 109,000 to 120,000 GEOs production guidance, although the agreement still depends on permitting, construction and final terms being completed.

Yet even with the earnings turnaround, investors should be aware that permitting delays or cost overruns at projects like Tartan and Los Azules could still...

Read the full narrative on McEwen (it's free!)

McEwen's narrative projects $631.8 million revenue and $350.0 million earnings by 2029. This requires 38.9% yearly revenue growth and a $275.9 million earnings increase from $74.1 million today.

Uncover how McEwen's forecasts yield a $32.10 fair value, a 67% upside to its current price.

Exploring Other Perspectives

The lowest analysts were already cautious, assuming revenue of about US$781.4 million and earnings of US$566.9 million by 2029, and their focus on execution risks at Grey Fox and Nevada satellites shows how differently you might weigh today’s production guidance and lab agreement against future delays or cost pressures.

Explore 7 other fair value estimates on McEwen - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your McEwen research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free McEwen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McEwen's overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com